Receptor-based assays in screening for biologically active substances.
Molecular biology has identified new receptors and ligands which are deregulated in diseases such as cancer and autoimmune conditions and which provide rational targets for therapeutic intervention. Advances in instrumentation and methodology make it possible to screen large numbers of samples in simple receptor-ligand binding assays in the search for drug candidates. Caution must be exercised in the interpretation of data derived from such assays. This is particularly pertinent to the recently characterized receptors, such as the cytokine receptors, as we do not fully understand the relationship between the receptor type and the linkage of receptors to the appropriate or inappropriate second messenger systems that are used in the experimental screening protocols and the disease state.
Xenova Ltd, Slough, UK.
I
I
Shaw
D006801:Humans; D007854:Lead / Q000032:analysis; D008024:Ligands; D011869:Radioligand Assay / Q000295:instrumentation / Q000379:methods; D011956:Receptors, Cell Surface / Q000032:analysis* / Q000378:metabolism
D008024:Ligands; D011956:Receptors, Cell Surface; D007854:Lead